Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau
- Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau
- 이수현; 이준석; 김윤경; 임성수; 신슬기; 정현정; 백자현
- histone deacetylase inhibitor; tau acetylation; tau aggregation; Alzheimer's disease
- Issue Date
- International journal of molecular sciences
- VOL 20-4283-12
- Epigenetic remodeling via histone acetylation has become a popular therapeutic strategy to
treat Alzheimer’s disease (AD). In particular, histone deacetylase (HDAC) inhibitors including M344 and SAHA have been elucidated to be new drug candidates for AD, improving cognitive abilities impaired in AD mouse models. Although emerged as a promising target for AD, most of the HDAC inhibitors are poorly selective and could cause unwanted side eects. Here we show that tau is one of the cytosolic substrates of HDAC and the treatment of HDAC inhibitors such as Scriptaid, M344, BML281, and SAHA could increase the level of acetylated tau, resulting in the activation of tau pathology.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.